| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 05/22/2009 | WO2009064457A2 Corticosteroid compositions |
| 05/22/2009 | WO2009063998A1 Nucleic acid having hydrophobic substance added thereto, and use thereof |
| 05/22/2009 | WO2009063995A1 Diagnosis and treatment of arteriosclerosis |
| 05/22/2009 | WO2009063962A1 Fat emulsion containing medicinal agent, and process for production thereof |
| 05/22/2009 | WO2009063921A1 Method of improving sweetness qualities of stevia extract |
| 05/22/2009 | WO2009063916A1 Aqueous film coating solution, film coating granule, and tablet comprising the film coating granule |
| 05/22/2009 | WO2009063484A2 Stable pharmaceutical composition of lamotrigine |
| 05/22/2009 | WO2009063081A2 Composition comprising at least one nucleosidic moiety as a therapeutic agent, and ckc. |
| 05/22/2009 | WO2009062960A1 Formulations for taci-immunoglobulin fusion proteins |
| 05/22/2009 | WO2009062399A1 Peptide ligand directed drug delivery |
| 05/22/2009 | WO2009062398A1 Novel thermosensitive liposomes containing therapeutic agents |
| 05/22/2009 | WO2009062356A1 Non-gelatin enteric hard capsule shell and preparation method thereof |
| 05/22/2009 | WO2009062313A1 Composition containing granulocyte colony stimulating factor (gcsf) for hair growth |
| 05/22/2009 | WO2009062299A1 Gel-stabilized liposome compositions, methods for their preparation and uses thereof |
| 05/22/2009 | WO2009048945A8 Rapid mucosal gel or film insulin compositions |
| 05/22/2009 | WO2009000504A3 Injectable formulation for photodynamic therapy |
| 05/22/2009 | WO2008116111A3 Growth factor mediated cosmeceuticals and use thereof to enhance skin quality |
| 05/22/2009 | WO2008073851A3 Remotely triggered release from heatable surfaces |
| 05/22/2009 | CA2705681A1 Corticosteroid compositions |
| 05/22/2009 | CA2705357A1 Formulations for taci-immunoglobulin fusion proteins |
| 05/22/2009 | CA2705289A1 Production of cytotoxic antibody-toxin fusion in eukaryotic algae |
| 05/22/2009 | CA2705031A1 Gel-stabilized liposome compositions, methods for their preparation and uses thereof |
| 05/22/2009 | CA2704949A1 Gastrointestinal delivery systems |
| 05/22/2009 | CA2704258A1 Novel thermosensitive liposomes containing therapeutic agents |
| 05/22/2009 | CA2703008A1 Anthelmintic paste comprising praziquantel, a macrolide lactone, cyclodextrin and a thickener |
| 05/21/2009 | US20090133134 Method and composition for genetically modifying non-human cells and animals |
| 05/21/2009 | US20090131949 delivering a bone substitue, water combinable combination of a calcium phosphate and a strontium phosphate and a salt of H3PO4; cement system for filling bone defects in a form-fit manner where the cement preparations are hardenable not only at room temperature, but also at body temperature; osteoporosis |
| 05/21/2009 | US20090131645 used to control the interaction of particular cell types with their external environment; for chronic pain; reduced side effects, long-lasting actions that do not require frequent injections or long-term catheterization; does not lead to tolerance and associated dependence |
| 05/21/2009 | US20090131641 Method for assembling subunits into capsoids |
| 05/21/2009 | US20090131639 Antibody-containing solution formulations |
| 05/21/2009 | US20090131542 Emulsifier Combination, Emulsion Containing the Emulsifier Combination, and a Process for its Production |
| 05/21/2009 | US20090131541 Gelatin-containing topical composition |
| 05/21/2009 | US20090131540 Biodegradable Magnesium Based Metallic Material for Medical Use |
| 05/21/2009 | US20090131534 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131533 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131526 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131525 Administering L-lysine-d-amphetamine or salts |
| 05/21/2009 | US20090131516 for treatment of attention deficit hyperactivity disorder, narcolepsy; bioavailability |
| 05/21/2009 | US20090131487 calixarenes having acyclic isophthalic acid groups attached, used as target for platelet derived growth factors or vascular endothelial growth factors, angiogenesis inhibitors, antiproliferative, antitumor or anticarcinogenic agents |
| 05/21/2009 | US20090131476 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131387 Transdermal formulation containing androgen, macrocyclic ester or ketone enhancer and thickener; extended time high blood serum concentration; rapidly absorbed gel; treatment of male hypogonadism |
| 05/21/2009 | US20090131347 Immunization-free methods for treating antigen-stimulated inflammation in a mammalian host and shifting the host's antigen immune responsiveness to a th1 phenotype |
| 05/21/2009 | US20090131335 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131334 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131333 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131332 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131326 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131325 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131324 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131323 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131322 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131277 Prostate cancer diagnosis and treatment |
| 05/21/2009 | US20090131259 Hydroxypolyamide Gel Forming Agents |
| 05/21/2009 | US20090130444 calcium phosphates in granular form having an X-ray diffraction pattern characteristic of hydroxyapatite in which a portion of the anions of the crystal structure are substituted with carbonate anions ( Ca10(PO4)6(OH)2-2x(CO3)x, X= 0 or 1); good compressibility and flow properties; used as excipient |
| 05/21/2009 | US20090130224 Granular bleach-activating mixtures |
| 05/21/2009 | US20090130217 Cosmetic Composition Containing Nanoparticulate a-Alumina |
| 05/21/2009 | US20090130204 Dosage Form Comprising Therapeutic Formulation |
| 05/21/2009 | US20090130199 Preparations, Methods And Kits Useful For The Treatment of Cough |
| 05/21/2009 | US20090130186 Wound dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan and incorporating silver nanoparticles |
| 05/21/2009 | US20090130184 Compositions and methods for preventing or reducing postoperative ileus and gastric stasis |
| 05/21/2009 | US20090130178 Formulation for decreasing tobacco, alcohol, drug or food consumption |
| 05/21/2009 | US20090130153 Emulsifier Combination, Emulsion Containing the Emulsifier Combination, and a Process for its Production |
| 05/21/2009 | US20090130145 Vaccine |
| 05/21/2009 | US20090130078 Treatment for Cardiovascular Disease |
| 05/21/2009 | US20090130050 Titanium Oxide Composite Particles, Dispersion Liquid Thereof, and Process for Producing Them |
| 05/21/2009 | US20090130043 Contains perhydro-4-ethyl-8,8a-dimethyl-1-naphthalenol |
| 05/21/2009 | US20090126732 Dry powder inhalation system for transpulmonary administration |
| 05/21/2009 | CA2644179A1 Novel pharmaceutical composition comprising a disintegration matrix |
| 05/20/2009 | EP2060573A2 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as medicine |
| 05/20/2009 | EP2060272A2 Vitamin-mitomycin conjugates |
| 05/20/2009 | EP2060271A1 Liposome and immunostimulating composition comprising the same |
| 05/20/2009 | EP2060262A1 Composition comprising at least one nucleosidic moiety as a therapeutic agent, and ckc |
| 05/20/2009 | EP2060259A1 Medical compositions for intravesical treatment of bladder cancer |
| 05/20/2009 | EP2060252A1 New formulation of galactosylceramide derivatives |
| 05/20/2009 | EP2060183A2 Enteric formulations of proanthocyanidin polymer antidiarrheal compositions |
| 05/20/2009 | EP2059527A2 Modified proteins |
| 05/20/2009 | EP2059261A1 Method for the production of conjugates of insulin-like growth factor-i and poly(ethylene glycol) |
| 05/20/2009 | EP2059260A2 Pharmaceutical compositions comprising hgh for oral delivery |
| 05/20/2009 | EP2059257A2 Use of glycolipids as adjuvants |
| 05/20/2009 | EP2059232A1 Use of polyols to obtain stable polymorphous forms of rifaximin |
| 05/20/2009 | EP2059231A1 Pharmaceutical compositions comprising cefquinome |
| 05/20/2009 | EP1737441A4 Beneficial effects of increasing local blood flow |
| 05/20/2009 | EP1578371A4 Compositions and methods for the diagnosis and treatment of tumor |
| 05/20/2009 | EP1562620B1 Modified cytokines for use in cancer therapy |
| 05/20/2009 | EP1352638B1 Cosmetics for alleviating skin irritation |
| 05/20/2009 | EP1330265B1 Formulations comprising dextrin polymers in combination with sugars for the delivery of nucleic acids |
| 05/20/2009 | EP1052974B1 Pharmaceutical formulation containing epothilone |
| 05/20/2009 | DE102007055341A1 Stabilisierung öliger Suspensionen enthaltend hydrophobe Kieselsäuren Stabilization oily suspensions containing hydrophobic silicas |
| 05/20/2009 | CN101437935A Method of producing s-adenosyl-l-methionine-containing dry yeast having excellent storage stability, the product thereof and composition for oral intake |
| 05/20/2009 | CN101437866A Novel O-carboxy anhydrides (OCAS) comprising a salifiable function and polymers obtained from these OCAS |
| 05/20/2009 | CN101437853A Biocompatible three dimensional matrix for the immobilization of biological substances |
| 05/20/2009 | CN101437852A Anti-TAT226 antibodies and immunoconjugates |
| 05/20/2009 | CN101437851A Cancerous disease modifying antibodies for diagnostic and therapeutic use in breast and prostate cancer |
| 05/20/2009 | CN101437548A The staudinger reaction in imaging and therapy and kits for use in imaging and therapy |
| 05/20/2009 | CN101437546A Transmucosal composition |
| 05/20/2009 | CN101437545A Hydrogel sheet and production method thereof |
| 05/20/2009 | CN101437544A Chemically modified polycation polymer for siRNA delivery |
| 05/20/2009 | CN101437536A Anti-tumor cell antigen antibody therapeutics |
| 05/20/2009 | CN101434646A Amphiprotic compound and use thereof |
| 05/20/2009 | CN101434631A Estra nitrate ester medicament for inhibiting angiogenesis |